Exchange: NASDAQ·Updated 07:30 PM EST

OBX News

News
all
press releases
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics, Inc. (Obsidian) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026...
Business Wire
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics, Inc. (Obsidian) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026...
Business Wire
More News
Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX) shares roseread more...
Benzinga
Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced positive updated results in patients with immune-checkpoint inhibitor...
Business Wire
Obsidian Therapeutics, Inc. (Obsidian) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with...
Business Wire
Obsidian Therapeutics, Inc. (Obsidian) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the first patient has been enrolled in the registration-enabling...
Business Wire
Obsidian Therapeutics, Inc. (Obsidian) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the completion of its previously announced transaction with...
Business Wire

Advertisement|Remove ads.